Go Pro
→ Bank of America grew this stake 139% (From Behind the Markets) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q1 2025 Earnings Report

HeartSciences logo
$2.80 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
-$2.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q1 2025
Date
9/12/2024
Time
N/A
Conference Call Date
Thursday, September 12, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

HeartSciences' Q1 2027 earnings is estimated for Thursday, September 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, September 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

HeartSciences' Q1 2025 Press ReleasePress Release
(8-K)
HeartSciences' Q1 2025 Quarterly reportQuarterly report
(10-Q)

HeartSciences Earnings Headlines

HeartSciences Inc.: Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69354233-heartsciences-inc-fortitude-invests-dollar-1-0-million-in-heartsciences-at-a-22-premium-with-no-adjustment-to-the-merger-consideration-399.htm
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fortitude-invests-1-0-million-130000623.html
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.tc pixel
 |  Golden Portfolio (Ad)
HeartSciences Announces $1 Million Fortitude Investment at 22% Premium Ahead of Proposed Merger
August 19, 2026  |  quiverquant.comQ
HeartSciences Completes Private Placement to Support Merger
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-completes-private-placement-to-support-merger?utm_source=marketbeat.com&utm_medium=referral
HeartSciences Receives Nasdaq Notice on Equity Noncompliance
August 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-receives-nasdaq-notice-on-equity-noncompliance?utm_source=marketbeat.com&utm_medium=referral
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools